Literature DB >> 25392221

Ebola virus transmission in guinea pigs.

Gary Wong1, Xiangguo Qiu2, Jason S Richardson2, Todd Cutts2, Brad Collignon3, Jason Gren2, Jenna Aviles4, Carissa Embury-Hyatt3, Gary P Kobinger5.   

Abstract

UNLABELLED: Ebola virus (EBOV) transmission is currently poorly characterized and is thought to occur primarily by direct contact with infectious material; however transmission from swine to nonhuman primates via the respiratory tract has been documented. To establish an EBOV transmission model for performing studies with statistical significance, groups of six guinea pigs (gps) were challenged intranasally (i.n.) or intraperitoneally (i.p.) with 10,000 times the 50% lethal dose (LD50) of gp-adapted EBOV, and naive gps were then introduced as cage mates for contact exposure at 1 day postinfection (p.i.). The animals were monitored for survival and clinical signs of disease and quantitated for virus shedding postexposure. Changes in the duration of contact of naive gps with infected animals were evaluated for their impact on transmission efficiency. Transmission was more efficient from i.n.- than from i.p.-challenged gps, with 17% versus 83% of naive gps surviving exposure, respectively. Virus shedding was detected beginning at 3 days p.i. from both i.n.- and i.p.-challenged animals. Contact duration positively correlated with transmission efficiency, and the abrogation of direct contact between infected and naive animals through the erection of a steel mesh was effective at stopping virus spread, provided that infectious animal bedding was absent from the cages. Histopathological and immunohistochemical findings show that i.n.-infected gps display enhanced lung pathology and EBOV antigen in the trachea, which supports increased virus transmission from these animals. The results suggest that i.n.-challenged gps are more infectious to naive animals than their systemically infected counterparts and that transmission occurs through direct contact with infectious materials, including those transported through air movement over short distances. IMPORTANCE: Ebola is generally thought to be spread between humans though infectious bodily fluids. However, a study has shown that Ebola can be spread from pigs to monkeys without direct contact. Further studies have been hampered, because an economical animal model for Ebola transmission is not available. To address this, we established a transmission model in guinea pigs and determined the mechanisms behind virus spread. The survival data, in addition to microscopic examination of lung and trachea sections, show that mucosal infection of guinea pigs is an efficient model for Ebola transmission. Virus spread is increased with longer contact times with an infected animal and is possible without direct contact between an infected and a naive host but can be stopped if infectious materials are absent. These results warrant consideration for the development of future strategies against Ebola transmission and for a better understanding of the parameters involved in virus spread.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25392221      PMCID: PMC4300644          DOI: 10.1128/JVI.02836-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Update: filovirus infection in animal handlers.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1990-04-06       Impact factor: 17.586

2.  Viral haemorrhagic fever in imported monkeys.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1992-05-08

3.  Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus.

Authors:  E Johnson; N Jaax; J White; P Jahrling
Journal:  Int J Exp Pathol       Date:  1995-08       Impact factor: 1.925

4.  Molecular characterization of guinea pig-adapted variants of Ebola virus.

Authors:  V E Volchkov; A A Chepurnov; V A Volchkova; V A Ternovoj; H D Klenk
Journal:  Virology       Date:  2000-11-10       Impact factor: 3.616

5.  Pathogenesis of experimental Ebola virus infection in guinea pigs.

Authors:  B M Connolly; K E Steele; K J Davis; T W Geisbert; W M Kell; N K Jaax; P B Jahrling
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

6.  Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure.

Authors:  T H Roels; A S Bloom; J Buffington; G L Muhungu; W R Mac Kenzie; A S Khan; R Ndambi; D L Noah; H R Rolka; C J Peters; T G Ksiazek
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

7.  Experimental inoculation of plants and animals with Ebola virus.

Authors:  R Swanepoel; P A Leman; F J Burt; N A Zachariades; L E Braack; T G Ksiazek; P E Rollin; S R Zaki; C J Peters
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

8.  Experimental aerosolized guinea pig-adapted Zaire ebolavirus (variant: Mayinga) causes lethal pneumonia in guinea pigs.

Authors:  N A Twenhafel; C I Shaia; T E Bunton; J D Shamblin; S E Wollen; L M Pitt; D R Sizemore; M M Ogg; S C Johnston
Journal:  Vet Pathol       Date:  2014-05-14       Impact factor: 2.221

9.  Preliminary report: isolation of Ebola virus from monkeys imported to USA.

Authors:  P B Jahrling; T W Geisbert; D W Dalgard; E D Johnson; T G Ksiazek; W C Hall; C J Peters
Journal:  Lancet       Date:  1990-03-03       Impact factor: 79.321

Review 10.  Ecologic and geographic distribution of filovirus disease.

Authors:  A Townsend Peterson; John T Bauer; James N Mills
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

View more
  27 in total

1.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs.

Authors:  Mable Chan; Frederick W Holtsberg; Hong Vu; Katie A Howell; Anders Leung; Evelyn Van der Hart; Paul H Walz; M Javad Aman; Shantha Kodihalli; Darwyn Kobasa
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

3.  Development of an anti-guinea pig CD4 monoclonal antibody for depletion of CD4+ T cells in vivo.

Authors:  Brianne N Banasik; Clarice L Perry; Celeste A Keith; Nigel Bourne; Hubert Schäfer; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2019-08-14       Impact factor: 2.303

4.  Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease.

Authors:  Robert Kozak; Shihua He; Andrea Kroeker; Marc-Antoine de La Vega; Jonathan Audet; Gary Wong; Chantel Urfano; Kym Antonation; Carissa Embury-Hyatt; Gary P Kobinger; Xiangguo Qiu
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

5.  Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.

Authors:  Matthias Lingemann; Xueqiao Liu; Sonja Surman; Bo Liang; Richard Herbert; Ashley D Hackenberg; Ursula J Buchholz; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

6.  Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Authors:  Michelle Meyer; Tania Garron; Ndongala M Lubaki; Chad E Mire; Karla A Fenton; Curtis Klages; Gene G Olinger; Thomas W Geisbert; Peter L Collins; Alexander Bukreyev
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

7.  Transcriptional Profiling of the Immune Response to Marburg Virus Infection.

Authors:  John H Connor; Judy Yen; Ignacio S Caballero; Sara Garamszegi; Shikha Malhotra; Kenny Lin; Lisa Hensley; Arthur J Goff
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

8.  Ebola Virus Shedding and Transmission: Review of Current Evidence.

Authors:  Pauline Vetter; William A Fischer; Manuel Schibler; Michael Jacobs; Daniel G Bausch; Laurent Kaiser
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226

Review 9.  Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

Authors:  Michelle Meyer; Delphine C Malherbe; Alexander Bukreyev
Journal:  Trends Microbiol       Date:  2018-09-07       Impact factor: 17.079

10.  ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus.

Authors:  Bing Yang; Alison Schaefer; Ying-Ying Wang; Justin McCallen; Phoebe Lee; Jay M Newby; Harendra Arora; Priya A Kumar; Larry Zeitlin; Kevin J Whaley; Scott A McKinley; William A Fischer; Dimple Harit; Samuel K Lai
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.